MIM
DRUG

MetLife Investment Management’s Bright Minds Biosciences DRUG Stock Holding History

MetLife Investment Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$285K Buy
3,911
+993
+34% +$79.9K ﹤0.01% 2031
2025
Q4 		$228K Hold
2,918
– – ﹤0.01% 2204
2025
Q3 		$177K Buy
+2,918
New +$113K ﹤0.01% 2388

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

MetLife Investment Management's DRUG Position: Q1 2026 in Review

MetLife Investment Management increased its Bright Minds Biosciences (DRUG) stake by 34% in Q1 2026, buying an estimated $79.9K and bringing the position to 3,911 shares worth $285K. The position accounts for ﹤0.01% of the portfolio, ranked #2031.

MetLife Investment Management first reported a position in DRUG in Q3 2025 and has held it in 3 quarters since. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • MetLife Investment Management held 3,911 shares of Bright Minds Biosciences worth $285K as of Q1 2026.
  • MetLife Investment Management bought 993 Bright Minds Biosciences shares in Q1 2026, an estimated $79.9K.
  • Bright Minds Biosciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2031 holding.
  • MetLife Investment Management first reported a position in Bright Minds Biosciences in Q3 2025 and has held it in 3 quarters since.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.